Other Corporate Information

• 4 Mar, 2025
  Spago Nanomedical proceeds with increased dose in the phase I/IIa study Tumorad-01
• 4 Mar, 2025
  Spago Nanomedical går vidare med ökad dos i fas I/IIa-studien Tumorad-01
• 15 Jan, 2025
  Spago Nanomedicals artikel med kliniska resultat från SPAGOPIX-01 accepterad för publicering i Investigative Radiology
• 15 Jan, 2025
  Spago Nanomedical article on SPAGOPIX-01 clinical results accepted for publication in Investigative Radiology
• 18 Dec, 2024
  Second patient group successfully dosed in Spago Nanomedical’s Phase I/IIa study Tumorad-01
• 18 Dec, 2024
  Andra patientgruppen framgångsrikt doserad i Spago Nanomedicals fas I/IIa-studie Tumorad-01
• 1 Oct, 2024
  Spago Nanomedical i ny fas med fullt fokus på Tumorad-programmet
• 1 Oct, 2024
  Spago Nanomedical in new phase with full focus on the Tumorad program
• 27 Aug, 2024
  Spago Nanomedicals fas I/IIa-studie Tumorad-01 fortsätter efter framgångsrikt slutförd behandling av första patientgruppen
• 27 Aug, 2024
  Spago Nanomedical’s Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group